Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28689042 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL28678429 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL28694879 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL16261204 | 0.80 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL21925677 | 0.79 | BRD4 (0.40) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL4138945 | 0.77 | RAPGEF4 (0.42) | ALDH1A1POLBSMN1; SMN2MAPTHPGD | |
| SCHEMBL1794606 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL21962890 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL21028198 | 0.77 | ALDH1A1 (0.43) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT | |
| SCHEMBL16261200 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901470-B1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | ALDH1A1 2584/4885LMNA 1261/4885POLB 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.